Positron Emission Tomography Using 11C Topotecan in Predicting Response to Treatment in Patients With Brain Metastases Due to Ovarian, Small Cell Lung, or Other Cancer
- Determine if tumor uptake of ^11C topotecan occurs quickly enough and at sufficient
concentration to be measured immediately following infusion in patients with brain
metastases secondary to ovarian cancer, small cell lung cancer, or other cancers.
- Determine, preliminarily, if ^11C imaging has potential to be an early predictor of
response to topotecan therapy in these patients.
- Determine the whole-body biodistribution of ^11C topotecan in these patients.
- Phase I: Patients receive ^11C topotecan IV over 10 minutes followed immediately by a
1-2 hour positron emission tomography (PET) scan. Within 4 weeks after initial imaging,
patients also undergo a CT scan.
- Phase II: Patients receive ^11C topotecan and undergo imaging as in phase I. Patients
also receive fludeoxyglucose F 18 IV and, 1 hour later, undergo a PET scan.
PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Pharmacokinetics on day of positron-emission tomography scan
Within 1 week of PET
Raymond Muzic, PhD
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
United States: Federal Government
|Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center||Cleveland, Ohio 44106-5065|